Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.
Saved in:
| Title: | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19. |
|---|---|
| Authors: | Robinson P; Infectious Disease, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA., Toussi SS; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Pearl River, New York, USA., Aggarwal S; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Bergman A; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA., Zhu T; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA., Hackman F; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Sathish JG; Drug Safety Unit, Pfizer Inc, Pearl River, New York, USA., Updyke L; Drug Safety Unit, Pfizer Inc, Cambridge, Massachusetts, USA., Loudon P; Tenpoint Therapeutics, Cambridge, UK., Krishna G; El Camino Health, Mountain View, California, USA., Clevenbergh P; University Hospital Brugmann, Brussels, Belgium., Hernandez-Mora MG; Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain., Cisneros Herreros JM; Hospital Universitario Virgen Del Rocio, Sevilla, Spain., Albertson TE; UC Davis Medical Center, Sacramento, California, USA., Dougan M; Massachusetts General Hospital, Boston, Massachusetts, USA., Thacker A; Regional One Health, Memphis, Tennessee, USA., Baniecki ML; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Soares H; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Whitlock M; Early Clinical Development, Pfizer Inc, Cambridge, UK., Nucci G; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Menon S; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Anderson AS; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Binks M; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK. |
| Source: | Open forum infectious diseases [Open Forum Infect Dis] 2023 Jul 10; Vol. 10 (8), pp. ofad355. Date of Electronic Publication: 2023 Jul 10 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37559753 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Robinson+P%22">Robinson P</searchLink>; Infectious Disease, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA.<br /><searchLink fieldCode="AU" term="%22Toussi+SS%22">Toussi SS</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Pearl River, New York, USA.<br /><searchLink fieldCode="AU" term="%22Aggarwal+S%22">Aggarwal S</searchLink>; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bergman+A%22">Bergman A</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+T%22">Zhu T</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hackman+F%22">Hackman F</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Sathish+JG%22">Sathish JG</searchLink>; Drug Safety Unit, Pfizer Inc, Pearl River, New York, USA.<br /><searchLink fieldCode="AU" term="%22Updyke+L%22">Updyke L</searchLink>; Drug Safety Unit, Pfizer Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Loudon+P%22">Loudon P</searchLink>; Tenpoint Therapeutics, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Krishna+G%22">Krishna G</searchLink>; El Camino Health, Mountain View, California, USA.<br /><searchLink fieldCode="AU" term="%22Clevenbergh+P%22">Clevenbergh P</searchLink>; University Hospital Brugmann, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Hernandez-Mora+MG%22">Hernandez-Mora MG</searchLink>; Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Cisneros+Herreros+JM%22">Cisneros Herreros JM</searchLink>; Hospital Universitario Virgen Del Rocio, Sevilla, Spain.<br /><searchLink fieldCode="AU" term="%22Albertson+TE%22">Albertson TE</searchLink>; UC Davis Medical Center, Sacramento, California, USA.<br /><searchLink fieldCode="AU" term="%22Dougan+M%22">Dougan M</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Thacker+A%22">Thacker A</searchLink>; Regional One Health, Memphis, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Baniecki+ML%22">Baniecki ML</searchLink>; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Soares+H%22">Soares H</searchLink>; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Whitlock+M%22">Whitlock M</searchLink>; Early Clinical Development, Pfizer Inc, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Nucci+G%22">Nucci G</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Menon+S%22">Menon S</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Anderson+AS%22">Anderson AS</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Binks+M%22">Binks M</searchLink>; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101637045%22">Open forum infectious diseases</searchLink> [Open Forum Infect Dis] 2023 Jul 10; Vol. 10 (8), pp. ofad355. <i>Date of Electronic Publication: </i>2023 Jul 10 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Published+by+Oxford+University+Press+on+behalf+of+the+Infectious+Diseases+Society+of+America%22">Published by Oxford University Press on behalf of the Infectious Diseases Society of America </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101637045 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2328-8957 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223288957%22">23288957 </searchLink><i>NLM ISO Abbreviation: </i>Open Forum Infect Dis <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37559753 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/ofid/ofad355 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: ofad355 Titles: – TitleFull: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Robinson P – PersonEntity: Name: NameFull: Toussi SS – PersonEntity: Name: NameFull: Aggarwal S – PersonEntity: Name: NameFull: Bergman A – PersonEntity: Name: NameFull: Zhu T – PersonEntity: Name: NameFull: Hackman F – PersonEntity: Name: NameFull: Sathish JG – PersonEntity: Name: NameFull: Updyke L – PersonEntity: Name: NameFull: Loudon P – PersonEntity: Name: NameFull: Krishna G – PersonEntity: Name: NameFull: Clevenbergh P – PersonEntity: Name: NameFull: Hernandez-Mora MG – PersonEntity: Name: NameFull: Cisneros Herreros JM – PersonEntity: Name: NameFull: Albertson TE – PersonEntity: Name: NameFull: Dougan M – PersonEntity: Name: NameFull: Thacker A – PersonEntity: Name: NameFull: Baniecki ML – PersonEntity: Name: NameFull: Soares H – PersonEntity: Name: NameFull: Whitlock M – PersonEntity: Name: NameFull: Nucci G – PersonEntity: Name: NameFull: Menon S – PersonEntity: Name: NameFull: Anderson AS – PersonEntity: Name: NameFull: Binks M IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 07 Text: 2023 Jul 10 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 2328-8957 Numbering: – Type: volume Value: 10 – Type: issue Value: 8 Titles: – TitleFull: Open forum infectious diseases Type: main |
| ResultId | 1 |
